Developed here is a mitotic network comprising a signature of up to 54 genes, and including also sub-sets of genes within the signature, which can identify members by requiring higher correlation values for a signature gene. The present mitotic network provides for methods for prognosis and diagnosis of various cancers. The mitotic network is conserved across cancers exhibiting aberrant mitotic activity and several genes in the network act as therapeutic targets. Development of other inhibitors of mitosis can apply expression values of the genes in the mitotic network from patient tissue to select patients during clinical validation of the new drugs.
STATEMENT OF GOVERNMENTAL SUPPORT
 This work was supported under Contract No. DE-ACO2-05CH11231 awarded by the Department of Energy, and under Grant No. CA 126551 awarded by the National Institutes of Health/National Cancer Institute. The work is also supported in part under work for others Agreement (WFO) LB 06-002417 from Glaxo Smith Kline. The government has certain rights in the invention.